|
Acute myocardial infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
Wild-type mice, atherosclerotic mice with double knockout (DKO) of the low-density lipoprotein receptor and Apobec-1, and DKO mice treated with the Nox-inhibitor apocynin were studied at baseline and at 3 and 21 days after closed-chest MI.
|
30139430 |
2018 |
|
Adenocarcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Such APOBEC1-induced mutator phenotypes could play a role in the onset of esophageal adenocarcinomas.
|
25085003 |
2014 |
|
Adenocarcinoma Of Esophagus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
APOBEC1 could be involved in cancer promotion at the very early stages of carcinogenesis, as it is highly expressed in Barrett's esophagus, a condition often associated with esophageal adenocarcinoma.
|
25085003 |
2014 |
|
Adenoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
In addition, there was reduced expression in adenomas from compound Apc(min/+) apobec-1(-/-) mice of other mRNAs (including epidermal growth factor receptor, peroxisome proliferator-activated receptor delta, prostaglandin receptor EP4, and c-myc), each containing the apobec-1 consensus binding site within their 3'-UTR.
|
17875695 |
2007 |
|
Adenoma of small intestine
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we show that small intestinal adenoma formation is dramatically reduced in compound Apc(min/+) apobec-1(-/-) mice when compared with the parental Apc(min/+) strain.
|
17875695 |
2007 |
|
Anaplasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Apobec1 Promotes Neurotoxicity-Induced Dedifferentiation of Müller Glial Cells.
|
28150227 |
2017 |
|
Arteriosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
RE4 APOBEC-1 transgenic mice should prove valuable for studying the roles of apoB-containing lipoproteins in lipid metabolism and atherosclerosis.
|
9633945 |
1998 |
|
Arteriosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Whereas Ldlr(-/-)Apobec1(-/-) mice fed a western-type diet and injected with a control AAV8.null vector experienced a further 65% progression in atherosclerosis over 2 months compared with baseline mice, Ldlr(-/-)Apobec1(-/-) mice treated with AAV8.mLDLR realized an 87% regression of atherosclerotic lesions after 3 months compared to baseline mice.
|
20976059 |
2010 |
|
Arteriosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Here, we placed hypercholesterolemic Ldlr-/-Apobec1-/- mice on a high-fat diet and treated them with either 25 mg/kg/day of clopidogrel (CLO) or 180 mg/kg/day of TIC for 16 weeks and evaluated the extent of atherosclerosis.
|
31242230 |
2019 |
|
Atherosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Here, we placed hypercholesterolemic Ldlr-/-Apobec1-/- mice on a high-fat diet and treated them with either 25 mg/kg/day of clopidogrel (CLO) or 180 mg/kg/day of TIC for 16 weeks and evaluated the extent of atherosclerosis.
|
31242230 |
2019 |
|
Atherosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Whereas Ldlr(-/-)Apobec1(-/-) mice fed a western-type diet and injected with a control AAV8.null vector experienced a further 65% progression in atherosclerosis over 2 months compared with baseline mice, Ldlr(-/-)Apobec1(-/-) mice treated with AAV8.mLDLR realized an 87% regression of atherosclerotic lesions after 3 months compared to baseline mice.
|
20976059 |
2010 |
|
Atherosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
RE4 APOBEC-1 transgenic mice should prove valuable for studying the roles of apoB-containing lipoproteins in lipid metabolism and atherosclerosis.
|
9633945 |
1998 |
|
Barrett Esophagus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
APOBEC1 could be involved in cancer promotion at the very early stages of carcinogenesis, as it is highly expressed in Barrett's esophagus, a condition often associated with esophageal adenocarcinoma.
|
25085003 |
2014 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The 'auxiliary' components of the apo B mRNA editing enzyme-complex are missing in many tumors including colorectal and gastric carcinoma, but are highly expressed in hepatocellular, lung adeno- and breast carcinoma all of which lack APOBEC-1.
|
10597235 |
1999 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Currently, there is no evidence that aberrant editing mediated by APOBEC-1 contributes to the tumorigenesis of natural human carcinomas.
|
10597235 |
1999 |
|
Carcinogenesis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Apobec-1 is an RNA-specific cytidine deaminase whose forced overexpression in transgenic animals is associated with hepatic carcinogenesis.
|
9797364 |
1998 |
|
Carcinogenesis
|
0.040 |
GeneticVariation
|
phenotype |
BEFREE |
At an experimental level mouse APOBEC1 is remarkable among 12 mammalian A1 enzymes in that it represents a source of somatic mutations in mouse genome, potentially fueling oncogenesis.
|
31726973 |
2019 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
APOBEC1 could be involved in cancer promotion at the very early stages of carcinogenesis, as it is highly expressed in Barrett's esophagus, a condition often associated with esophageal adenocarcinoma.
|
25085003 |
2014 |
|
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Currently, there is no evidence that aberrant editing mediated by APOBEC-1 contributes to the tumorigenesis of natural human carcinomas.
|
10597235 |
1999 |
|
Cerebral Infarction
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Apobec-1 could upregulate COX-2 expression in neurogenic cells by stabilizing COX-2 mRNA, and might aggravate injury of oxygen-glucose deprivation in neurogenic cells as well as in rats with cerebral ischemia.
|
23609497 |
2013 |
|
Childhood Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Murine APOBEC1 was able to hyperdeaminate cytidine residues in murine leukemia virus genomic RNA as well.
|
18983852 |
2009 |
|
Cholecystolithiasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the investigated German samples, no evidence of association of APOBEC1 and PPARG with gallstone susceptibility was detected.
|
17696929 |
2007 |
|
Cholelithiasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
To investigate APOBEC1 and PPARG as candidate genes for common symptomatic gallstone disease in humans.
|
17696929 |
2007 |
|
Colon Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Apobec-1 mRNA was detectable in normal and colon cancer tissue, metastatic nodules, and certain colon cancer-derived cell lines.
|
9797364 |
1998 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Adenovirus-mediated apobec-1 introduction into HCA-7 (colorectal cancer) cells showed a dose-dependent increase in Cox-2 protein and stabilization of endogenous Cox-2 mRNA.
|
17875695 |
2007 |